Patent · US Active

BCMA-binding antibodies and uses thereof

US11401336B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

CELGENE CORPORATION · US

Inventors

Mahan Abbasian · San Diego, US
Henry Hin Lee Chan
Kandasamy Hariharan · San Diego, US
Jeonghoon Sun · Thousand Oaks, US
Andrew Wurmser · San Diego, US

Key dates

Filing date	Feb 20, 2019
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Feb 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/565
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.